Literature DB >> 2850002

Preparation of neo-galactosylated liposomes and their interaction with mouse peritoneal macrophages.

J Haensler1, F Schuber.   

Abstract

In order to target liposomes to cells expressing at their surface a galactose-binding site we have prepared liposomes containing new synthetic galactolipids. Neo-galactosylated liposomes were prepared by covalently coupling beta-D-1-thiogalactopyranoside residues, substituted with a hydrophilic spacer-arm and functionalized with a sulfhydryl group, to preformed large unilamelar vesicles containing 4-(p-maleimidophenyl)butyryl phosphatidylethanolamine. The vesicles, having a galactose content above a threshold value of about 5 mol%, could be aggregated with Ricinus communis agglutinin. This aggregation was reversed by addition of excess free methyl beta-D-galactopyranoside, indicating that the surface glucidic moieties of these liposomes were accessible to the lectin. Compared to the control vesicles, the neo-galactosylated liposomes (containing 15 mol% galactose) presented in vitro an increased binding to cell possessing a beta-D-galactose specific receptor, i.e. resident mouse peritoneal macrophages. At 4 degrees C, the specific binding was about 2-fold, whereas at 37 degrees C it was increased to about 4-5-fold. This differential binding was largely unaffected by serum and, interestingly was much dependent on the degree of galactosylation of the liposomes, i.e. a threshold value of 5 mol% was needed to observe an increased binding of the targeted vesicles to the macrophages.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2850002     DOI: 10.1016/0005-2736(88)90461-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

Review 1.  Bone marrow-targeted liposomal carriers.

Authors:  Keitaro Sou; Beth Goins; Babatunde O Oyajobi; Bruno L Travi; William T Phillips
Journal:  Expert Opin Drug Deliv       Date:  2011-01-31       Impact factor: 6.648

2.  Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level Box-Behnken design.

Authors:  Ajay B Solanki; Jolly R Parikh; Rajesh H Parikh
Journal:  AAPS PharmSciTech       Date:  2007-10-19       Impact factor: 3.246

3.  Synthetic glycopeptide-based delivery systems for systemic gene targeting to hepatocytes.

Authors:  K Anwer; M Logan; F Tagliaferri; M Wadhwa; O Monera; C H Tung; W Chen; P Leonard; M French; B Proctor; E Wilson; A Singhal; A Rolland
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

4.  Versatile synthesis of bi- and tri-antennary galactose ligands: interaction with the Gal/GalNAc receptor of human hepatoma cells.

Authors:  A Kichler; F Schuber
Journal:  Glycoconj J       Date:  1995-06       Impact factor: 2.916

5.  Influence of the galactosyl ligand structure on the interaction of galactosylated liposomes with mouse peritoneal macrophages.

Authors:  J Haensler; F Schuber
Journal:  Glycoconj J       Date:  1991-04       Impact factor: 2.916

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.